Insight Molecular fixes bylaws exhibit in 10-K
Insight Molecular Diagnostics Inc. filed a current report to correct an exhibit previously attached to its Annual Report on Form 10-K for the year ended December 31, 2025.
Rhea-AI Filing Summary
Insight Molecular Diagnostics Inc. filed a current report to correct an exhibit previously attached to its Annual Report on Form 10-K for the year ended December 31, 2025. The earlier filing inadvertently included shareholder voting provisions that are not part of the Company’s Third Amended and Restated Bylaws.
The Company is now providing the correct copy of its Third Amended and Restated Bylaws as Exhibit 3.1 to this report. The correction is described as a clerical error and does not change any other disclosures contained in the Form 10-K.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Form type: Form 8-K
Affected period: Year ended December 31, 2025
Corrected exhibit number: Exhibit 3.1
+2 more
5 metrics
Form type
Form 8-K
Current report correcting prior 10-K exhibit
Affected period
Year ended December 31, 2025
Annual Report on Form 10-K referenced
Corrected exhibit number
Exhibit 3.1
Third Amended and Restated Bylaws attached to 8-K
Prior exhibit reference
Exhibit 3.5
Incorrect bylaws version incorporated in Form 10-K
Filing date
April 30, 2026
Date of current report by Insight Molecular Diagnostics Inc.
Key Terms
Third Amended and Restated Bylaws, Item 8.01 Other Events, Annual Report on Form 10-K, exhibit, +1 more
5 terms
Third Amended and Restated Bylaws financial
"The Company’s Third Amended and Restated Bylaws (as amended and restated, the “Bylaws”) as Exhibit 3.5."
Item 8.01 Other Events regulatory
"Emerging growth company Item 8.01 Other Events On March 26, 2026, Insight Molecular Diagnostics Inc."
Annual Report on Form 10-K regulatory
"filed its Annual Report on Form 10-K for the year ended December 31, 2025"
An annual report on Form 10‑K is a required, comprehensive filing that publicly traded companies give to regulators and investors summarizing their business, results of operations, detailed financial statements reviewed by independent auditors, material risks, legal issues and management’s discussion of performance. Investors use it like a company’s year‑end report card and medical checkup: it reveals how the business made money, where it is vulnerable, and the facts needed to compare value, judge risk and make informed investment decisions.
exhibit regulatory
"Due to a clerical error, the exhibit inadvertently included certain provisions related to shareholder voting"
FAQ
What did Insight Molecular Diagnostics Inc. (IMDX) disclose in this 8-K filing?
Insight Molecular Diagnostics Inc. disclosed that a clerical error in its prior Form 10-K exhibit mis-stated certain shareholder voting provisions. The company is now filing the correct Third Amended and Restated Bylaws as Exhibit 3.1 without changing any other Form 10-K disclosures.
How does this 8-K affect Insight Molecular Diagnostics Inc.’s previously filed 10-K?
The 8-K states that only the bylaws exhibit is corrected, replacing an incorrect version that included extra shareholder voting provisions. The company specifically notes that this correction does not change any other disclosures contained in the previously filed Annual Report on Form 10-K.
What corporate document is being corrected for Insight Molecular Diagnostics Inc. (IMDX)?
The company is correcting its Third Amended and Restated Bylaws, previously incorporated by reference as Exhibit 3.5 to the Form 10-K. The new 8-K attaches the correct bylaws as Exhibit 3.1, removing provisions that were erroneously included in the prior exhibit.
Why did Insight Molecular Diagnostics Inc. need to refile its bylaws exhibit?
The bylaws exhibit in the Form 10-K inadvertently included certain shareholder voting provisions that are not actually part of the company’s bylaws. The 8-K attributes this to a clerical error and remedies it by filing the accurate Third Amended and Restated Bylaws as a new exhibit.
Does the 8-K report any financial changes for Insight Molecular Diagnostics Inc. (IMDX)?
The 8-K does not report financial changes. It focuses on correcting the bylaws exhibit that was incorporated into the Form 10-K for the year ended December 31, 2025, and explicitly states that no other disclosures in that annual report are changed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
